Pregnancy Outcome and Safety of Interrupting Therapy for Women With Endocrine Responsive
Breast Cancer (POSITIVE)
Is temporary interruption of endocrine therapy, with the goal to permit pregnancy,
associated with a higher risk of breast cancer recurrence?
Basic Study Information
Purpose:Location: University of Rochester Medical Center
The best available evidence suggests that pregnancy after breast cancer does not increase
a woman's risk of developing a recurrence from her breast cancer. In particular, the
most recent data suggest that this is the case also in women with a hormone receptor-positive
breast cancer. There is also no indication of increased risk for delivery complications
or for the newborn. The aim of the study is to investigate if temporary interruption
of endocrine therapy, with the goal to permit pregnancy, is associated with a higher
risk of breast cancer recurrence.The study aims also to evaluate different specific
indicators related to fertility, pregnancy and breast cancer biology in young women.
A psycho-oncological companion study on fertility concerns, psychological well-being
and decisional conflicts will be conducted in interested Centers.
Study Reference #: CBRS18134
Lead Researcher (Principal Investigator)
Lead Researcher: Alissa Huston
Study Contact InformationStudy Coordinator: Laura Mitchell
Phone: (585) 275-7763
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search